



Aarti Drugs Limited

Manufacturers of : Bulk Drugs & Chemicals

Corporate Office : Mahendra Industrial Estate,
Ground Floor, Plot No. 109-D, Road No. 29,
Sion (East), Mumbai - 400 022. (India)
Tel.: 022-2407 2249 / 2401 9025 (30 Lines)
Fax.: 022-2407 3462 / 2407 0144
Email: admin@aartidrugs.com
website: www.aartidrugs.com
CIN No.:L37060MH1984PLC055433

Ref: ADL/SE/2016-17

Date: 5th May, 2016

To,

Department of Corporate Services
BSE Limited
Phiroze Jeejeebhoy Towers,
Dalal Street,
Mumbai - 400 001
BSE CODE - 524348
BSE ID - AARTIDRUGS

National Stock Exchange of India
Limited
"Exchange Plaza",
Bandra - Kurla Complex,
Bandra(E), Mumbai - 400 051
NSE CODE: AARTIDRUGS

Sub: Outcome of Board Meeting held today i.e. 5th May, 2016 pursuant to Regulation 33 and Regulation 30 read with Para A of Part A of Schedule III of SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015

Dear Sir,

Pursuant to Regulation 33 and Regulation 30 read with Para A of Part A of Schedule III of SEBI (Listing Obligation & Disclosure Requirements) Regulations, 2015, we inform you that the Board of Directors at its Meeting held today i.e. Thursday, 5th May, 2016 had *inter-alia* considered and approved the Audited Financial Results (Standalone & Consolidated) for the Quarter and Year ended 31st March, 2016. Accordingly, please find enclosed herewith the following:

1. Statement of Audited Financial Results (Standalone & Consolidated) for the Quarter and Year ended on 31st March, 2016 alongwith report of the Statutory Auditors and
2. Form A of Audit Report with unmodified opinion

Kindly take the same on your records and acknowledge receipt.

Thanking you,

Yours faithfully,

For Aarti Drugs Limited

Vibhav S. Ranade

Company Secretary & Compliance Officer



Encl: A/A



Aarti Drugs Limited

Manufacturers of : Bulk Drugs & Chemicals

Corporate Office : Mahendra Industrial Estate,
Plot No. 109-D, Road No. 29, Sion (East),
Mumbai - 400 022. (India)
Tel.: 022-2407 2249 / 2401 9025 (30 Lines)
Fax : 022-2407 3462 / 2407 0144
Email : admin@aartidrugs.com
Website : www.aartidrugs.com
CIN NO : L37060MH1984PLC055433

AARTI DRUGS LIMITED											
STATEMENT OF AUDITED FINANCIAL RESULTS FOR THE QUARTER AND YEAR ENDED 31ST MARCH, 2016											
(Rs. in lacs except for share data)											
PART I	Sr. No.	Particulars	Standalone					Consolidated			
			Quarter Ended			Year Ended		Quarter Ended		Year Ended	
			31st Mar 2016 (Audited)	31st Dec 2015 (Audited)	31st Mar 2015 (Audited)	31st Mar 2016 (Audited)	31st Mar 2015 (Audited)	31st Mar 2016 (Audited)	31st Dec 2015 (Audited)	31st Mar 2016 (Audited)	31st Mar 2015 (Audited)
1		Income from Operations									
		(a) Gross Sales / Income from Operations	32,376	27,619	30,067	1,16,610	1,16,994	33,975	28,799	1,22,831	
		Less : Excise Duty & Sales Tax	2,681	2,322	2,306	9,536	8,546	2,578	2,299	9,342	
		(a) Net Sales / Income from Operations (Net Of Excise Duty & Sales Tax)	29,695	25,297	27,761	1,07,073	1,08,448	31,397	26,499	1,13,488	
		(b) Other Operating Income	51	375	76	476	274	64	367	496	
		Total income from operations (net)	29,746	25,672	27,837	1,07,550	1,08,722	31,461	26,867	1,13,984	
2		Expenditure									
		(a) Cost of materials consumed	16,235	14,799	15,630	68,298	67,844	16,704	15,281	72,102	
		(b) Purchase of stock-in-trade	514	665	1,192	3,652	8,721	1,464	1,101	5,060	
		(c) Changes in inventories of finished goods, work-in-progress and stock-in-trade	3,551	1,109	2,139	(525)	(2,358)	3,523	1,140	(491)	
		(d) Employee benefits expense	1,119	1,017	1,024	4,136	3,730	1,221	1,098	4,476	
		(e) Depreciation and Amortisation Expense	907	900	809	3,558	3,066	935	922	3,653	
		(f) Other expenses	3,952	3,829	3,561	14,818	13,889	3,974	3,923	15,269	
		Total expenses	26,279	22,319	24,355	93,938	94,893	27,821	23,465	1,00,068	
3		Profit from Operations before Other Income, finance costs and exceptional items (1-2)	3,466	3,353	3,482	13,612	13,829	3,640	3,402	13,916	
4		Other Income	-	-	-	-	65	-	-	-	
5		Profit from ordinary activities before finance cost and exceptional items (3+4)	3,466	3,353	3,482	13,612	13,894	3,640	3,402	13,916	
6		Finance costs (interest)	1,125	1,117	976	4,328	3,888	1,151	1,124	4,389	
7		Profit from ordinary activities after finance cost but before Exceptional Items (5-6)	2,341	2,236	2,506	9,284	10,006	2,489	2,278	9,527	
8		Exceptional Items	-	-	-	-	-	-	-	-	
9		Profit from Ordinary Activities before Tax (7-8)	2,341	2,236	2,506	9,284	10,006	2,489	2,278	9,527	
10		Tax Expenses	630	575	620	2,655	2,247	630	575	2,655	
		Provision for Taxation - Current	490	435	528	2,115	2,100	490	435	2,115	
		- MAT Credit Entitlement	-	-	(48)	-	(100)	-	-	(100)	
		- Earlier year	-	-	-	-	(153)	-	-	(153)	
		Provision for Deferred Taxation	140	140	140	540	400	140	140	540	
11		Net profit from ordinary Activities after Tax (9-10)	1,711	1,661	1,886	6,629	7,760	1,859	1,703	6,872	
12		Extraordinary items	-	-	-	-	-	-	-	-	
13		Net Profit for the Period (11+12)	1,711	1,661	1,886	6,629	7,760	1,859	1,703	6,872	
14		Shares of Profit/ (Loss) of associates	-	-	-	-	-	-	-	-	
15		Minority Interest	-	-	-	-	-	-	-	-	
16		Net Profit for the Period after taxes, minority interest and share of profit/ (loss) of associates (13+14+15)	1,711	1,661	1,886	6,629	7,760	1,859	1,703	6,872	
17		Paid-up Equity Share Capital of Rs.10/- each.	2,422	2,422	2,422	2,422	2,422	2,422	2,422	2,422	
18		Reserves & Surplus (excluding revaluation reserves)	-	-	-	32,610	27,949	-	-	33,318	
19		Earning per share (Diluted E P S (in Rs.) (of Rs. 10/- each) (not annualised))									
		(a) Basic & Diluted (before extraordinary items)	7.07	6.86	7.79	27.37	32.04	7.68	7.03	28.38	
		(b) Basic & Diluted (after extraordinary items)	7.07	6.86	7.79	27.37	32.04	7.68	7.03	28.38	

For AARTI DRUGS LIMITED

[Signature]

HARSHIT M. SAVLA

JT. MANAGING DIRECTOR

Place: Mumbai

Date: 5th May, 2016



Aarti Drugs Limited

Manufacturers of : Bulk Drugs & Chemicals

Corporate Office : Mahendra Industrial Estate,
Plot No. 109-D, Road No. 29, Sion (East),
Mumbai - 400 022. (India)
Tel.: 022-2407 2249 / 2401 9025 (30 Lines)
Fax : 022-2407 3462 / 2407 0144
Email : admin@aartidrugs.com
Website : www.aartidrugs.com
CIN NO : L37060MH1984PLC055433

STATEMENT OF ASSETS AND LIABILITIES AS AT 31ST MARCH, 2016 (Rs. in lacs)				
Particulars	Standalone		Consolidated	
	31st Mar 2016	31st Mar 2015	31st Mar 2016	31st Mar 2015
A EQUITY AND LIABILITIES				
1 Shareholder' funds				
(a) Share Capital	2,422	2,422	2,422	2,422
(b) Reserves and surplus	32,610	27,949	33,318	28,394
Total - Shareholders's funds	35,031	30,370	35,740	30,815
2 Non-current liabilities				
(a) Long - term borrowings	17,521	15,147	19,123	16,347
(b) Deferred tax liabilities (net)	4,041	3,501	4,042	3,502
(c) Other long - term liabilities	1,027	1,205	1,071	1,225
(d) Long - term provisions	142	29	142	29
Total - Non - current liabilities	22,731	19,883	24,378	21,103
3 Current liabilities				
(a) Short - term borrowings	25,737	25,127	25,841	25,243
(b) Trade payables	16,418	15,019	18,490	16,672
(c) Other current liabilities	4,224	4,119	4,380	4,153
(d) Short - term provisions	1,328	2,176	1,391	2,208
Total - current liabilities	47,708	46,440	50,102	48,276
TOTAL- EQUITY AND LIABILITIES	1,05,470	96,693	1,10,220	1,00,194
B ASSETS				
1 Non-current assets				
(a) Fixed assets (including CWIP)	49,681	44,483	52,746	46,452
(b) Non - current investments	1,112	1,111	463	463
(c) Long - term loans and advances	474	424	488	724
Total - Non - current assets	51,267	46,019	53,697	47,640
2 Current assets				
(a) Inventories	16,705	15,336	17,835	16,420
(b) Trade receivables	32,120	30,759	33,169	31,427
(c) Cash and cash equivalents	450	343	482	358
(d) Short - term loans and advances	1,884	1,745	1,924	1,765
(e) Other -Current assets	3,045	2,491	3,113	2,585
Total - current assets	54,203	50,674	56,522	52,554
TOTAL - ASSETS	1,05,470	96,693	1,10,220	1,00,194

Notes :

- The above results for the Quarter and Year ended 31st March, 2016 have been reviewed by the Audit Committee and approved by the Board of Directors in their meeting held on 5th May, 2016.
- The company has published consolidated financial Results from Quarter Ended September ,2015 in addition to stand alone Results, pursuance to decision taken by Board of Director in its Meeting held on july 31,2015, As a results the audited Financial Results of its only subsidiary , Pinnacle Life science Pvt. Ltd., for the Quarter Ended December 31,,2015 and March 31, 2016 has been included.
- Company is operating as a single segment company, engaged in pharmaceutical Business.
- Figures for the previous period have been regrouped or rearranged wherever necessary.
- The aforesaid Audited Financial Results will be uploaded on the Company's website www.aartidrugs.com and will also be available on the website of BSE Limited www.bseindia.com and the National Stock Exchange of India Limited www.nseindia.com for the benefit of the shareholders and investors.

For AARTI DRUGS LIMITED


HARSHIT M. SAVLA
JT. MANAGING DIRECTOR

Place: Mumbai
Date: 5th May,2016



Aarti Drugs Limited

Manufacturers of : Bulk Drugs & Chemicals

Corporate Office : Mahendra Industrial Estate,
Ground Floor, Plot No. 109-D, Road No. 29,
Sion (East), Mumbai - 400 022. (India)
Tel .: 022-2407 2249 / 2401 9025 (30 Lines)
Fax.: 022-2407 3462 / 2407 0144
Email: admin@aartidrugs.com
website: www.aartidrugs.com
CIN No.:L37060MH1984PLC055433

FORM A

(For audit report with unmodified opinion)

[Pursuant to Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015]

1.	Name of the Company	Aarti Drugs Limited
2.	Annual Financial Statement for the year ended	March 31, 2016 [Standalone]
3.	Type of Audit Observation	Un-Modified
4.	Frequency of Observation	Not Applicable

For Aarti Drugs Limited

Prakash M. Patil
Chairman, Managing Director & CEO
[DIN: 00005618]

For Gokhale & Sathe
Chartered Accountants
Firm Regn No. 103264W



Tejas Parikh
Partner
Membership No. 123215

Ramdas M. Gandhi
Chairman of Audit Committee
[DIN: 00029437]

Adhish P. Patil
Chief Financial Officer [CFO]





Auditor's Report on Quarterly Financial Results and Year to Date Results of AARTI DRUGS LIMITED Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

To
The Board of Directors of AARTI DRUGS LIMITED

We have audited the quarterly financial results of AARTI DRUGS LIMITED ('the Company') for the quarter ended March 31, 2016 and the year to date financial results for the period from April 1, 2015 to March 31, 2016, attached herewith, being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. These quarterly financial results as well as the year to date financial results have been prepared on the basis of the interim financial statements, which are the responsibility of the company's management. Our responsibility is to express an opinion on these financial results based on our audit of such interim financial statements, which have been prepared in accordance with the recognition and measurement principles laid down in Accounting Standard (AS) 25, on Interim Financial Reporting, specified under section 133 of the Companies Act, 2013 read with Rule 7 of the Companies (Accounts) Rules, 2014 and other accounting principles generally accepted in India.

We conducted our audit in accordance with the auditing standards generally accepted in India. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial results are free of material misstatement(s). An audit includes examining, on a test basis, evidence supporting the amounts disclosed as financial results. An audit also includes assessing the accounting principles used and significant estimates made by management. We believe that our audit provides a reasonable basis for our opinion.





In our opinion and to the best of our information and according to the explanations given to us these quarterly financial results as well as the year to date financial results:

- (i) are presented in accordance with the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 in this regard; and
- (ii) give a true and fair view of the net profit and other financial information for the quarter ended March 31, 2016 and year to date results for the period from April 1, 2015 to March 31, 2016.

For GOKHALE & SATHE
CHARTERED ACCOUNTANTS
Firm Registration No.: 103264W

CA TEJAS PARIKH
PARTNER
M. No. 123215
Mumbai,

Dated: May 5, 2016.





Aarti Drugs Limited

Manufacturers of : Bulk Drugs & Chemicals

Corporate Office : Mahendra Industrial Estate,
Ground Floor, Plot No. 109-D, Road No. 29,
Sion (East), Mumbai - 400 022. (India)
Tel. : 022-2407 2249 / 2401 9025 (30 Lines)
Fax.: 022-2407 3462 / 2407 0144
Email: admin@aartidrugs.com
website: www.aartidrugs.com
CIN No.:L37060MH1984PLC055433

FORM A

(For audit report with unmodified opinion)

[Pursuant to Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015]

1.	Name of the Company	Aarti Drugs Limited
2.	Annual Financial Statement for the year ended	March 31, 2016 [Consolidated]
3.	Type of Audit Observation	Un-Modified
4.	Frequency of Observation	Not Applicable

For Aarti Drugs Limited

Prakash M. Patil
Chairman, Managing Director & CEO
[DIN: 00005618]

For Gokhale & Sathe

Chartered Accountants

Firm Regn No. 103264W



Tejas Parikh
Partner
Membership No. 123215

Ramdas M. Gandhi
Chairman of Audit Committee
[DIN: 00029437]

Adhish P. Patil
Chief Financial Officer [CFO]





Auditor's Report on Quarterly Consolidated Financial Results and Year to Date Consolidated Financial Results of AARTI DRUGS LIMITED Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

To
Board of Directors of AARTI DRUGS LIMITED.

We have audited the quarterly consolidated financial results of AARTI DRUGS LIMITED ("the Company") for the quarter ended March 31, 2016, and the year to date consolidated financial results for the period from April 1, 2015 to March 31, 2016 attached herewith, being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. These quarterly consolidated financial results as well as the year to date consolidated financial results have been prepared from consolidated interim financial statements, which are the responsibility of the Company's management. Our responsibility is to express an opinion on these consolidated financial results based on our audit of such consolidated interim financial statements, which have been prepared in accordance with the recognition and measurement principles laid down in Accounting Standard (AS) 25, on Interim Financial Reporting, specified under section 133 of the Companies Act, 2013 read with Rule 7 of the Companies (Accounts) Rules, 2014 and other accounting principles generally accepted in India.

We conducted our audit in accordance with the auditing standards generally accepted in India. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial results are free of material misstatement(s). An audit includes examining, on a test basis, evidence supporting the amounts disclosed as financial results. An audit also includes assessing the accounting principles used and significant estimates made by management. We believe that our audit provides a reasonable basis for our opinion.

We did not audit financial statements/financial information of one subsidiary whose financial statement/financial information reflect total assets of Rs. 6,693.90 lakhs as at March 31, 2016 and total revenues of Rs.2,549.56 lakhs and Rs 8,584.07 lakhs for the quarter and year ended March 31, 2016 respectively as considered in the consolidated financial statements. These financial statements/ financial information have been audited by other auditor whose report have been furnished to us and our opinion on the consolidated financial statements, in so far as it relates to the amounts and disclosures included in respect of its subsidiary is based solely on the report of the other auditor.





In our opinion and to the best of our information and according to the explanations given to us these quarterly consolidated financial results as well as the year to date consolidated financial results:

- (i) include the quarterly financial results and year to date financial results of its only subsidiary, Pinnacle Life Science Private Limited
- (ii) have been presented in accordance with the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 in this regard; and
- (iii) give a true and fair view of the consolidated net profit and other financial information for the quarter ended March 31, 2016 and year to date consolidated results for the period from April 1, 2015 to March 31, 2016.

For GOKHALE & SATHE
CHARTERED ACCOUNTANTS
Firm Registration No.: 103264W

CA TEJAS PARIKH
PARTNER
M. No. 123215
Place: Mumbai
Date: May 5, 2016.

